N-[[4-[2-(5-甲基-2-苯基-4-恶唑基)乙氧基]苯基]甲基]甘氨酸甲酯 | 331746-65-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-[[4-[2-(5-甲基-2-苯基-4-恶唑基)乙氧基]苯基]甲基]甘氨酸甲酯
• 中文别名: N-[[4-[2-(5-甲基-2-苯基-4-噁唑)乙氧基]苯基]甲基]甘氨酸甲酯
• 英文名称: {4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzylamino}acetic acid methyl ester
• 英文别名: N-[[4-[2-(5-Methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine Methyl Ester；methyl 2-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methylamino]acetate
• CAS: 331746-65-7
• 化学式: C₂₂H₂₄N₂O₄
• 分子量: 380.444
• InChiKey: SLAOTPLLYBJKKI-UHFFFAOYSA-N

物化性质

• 熔点：
  61-65°C
• 沸点：
  549.6±60.0 °C(Predicted)
• 密度：
  1.165±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  73.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[[4-[2-(5-甲基-2-苯基-4-恶唑基)乙氧基]苯基]甲基]甘氨酸甲酯 在 lithium hydroxide 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.5h， 生成 莫格列地
  参考文献：
  名称：

  Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

  摘要：

  Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity in vitro at human PPAR alpha (EC50 = 320 nM) and PPAR gamma (EC50 = 110 nM). Compound 2 shows excellent efficacy for lowering glucose, insulin, triglycerides, and free fatty acids in genetically obese, severely diabetic db/db mice and has a favorable ADME profile. Compound 2 is currently in clinical development for the treatment of type 2 diabetes and dyslipidemia.

  DOI：

  10.1021/jm0496436
• 作为产物：
  描述：

  Methyl 2-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methylideneamino]acetate 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 3.5h， 以4.48 g的产率得到N-[[4-[2-(5-甲基-2-苯基-4-恶唑基)乙氧基]苯基]甲基]甘氨酸甲酯
  参考文献：
  名称：

  Design and Synthesis of N-[(4-Methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a Novel Peroxisome Proliferator-Activated Receptor α/γ Dual Agonist with Efficacious Glucose and Lipid-Lowering Activities

  摘要：

  Muraglitazar/BMS-298585 (2) has been identified as a non-thiazolidinedione PPAR alpha/gamma dual agonist that shows potent activity in vitro at human PPAR alpha (EC50 = 320 nM) and PPAR gamma (EC50 = 110 nM). Compound 2 shows excellent efficacy for lowering glucose, insulin, triglycerides, and free fatty acids in genetically obese, severely diabetic db/db mice and has a favorable ADME profile. Compound 2 is currently in clinical development for the treatment of type 2 diabetes and dyslipidemia.

  DOI：

  10.1021/jm0496436

文献信息

• [EN] PROCESS OF PREPARING SUBSTITUTED CARBAMATES AND INTERMEDIATES THEREOF<br/>[FR] PROCEDE DE PREPARATION DE CARBAMATES SUBSTITUES ET INTERMEDIAIRES DE CEUX-CI
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005113521A1

  公开（公告）日：2005-12-01

  An improved process of preparing substituted carbamate derivatives, and crystalline forms thereof, useful for the treatment of dyslipidemia and diabetes, and intermediates thereof are provided.

  提供了一种改进的制备替代氨基甲酸酯衍生物及其结晶形式的过程，用于治疗血脂异常和糖尿病，以及其中间体。
• Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
  申请人：Bristol-Myers Squibb Company

  公开号：US06414002B1

  公开（公告）日：2002-07-02

  Compounds are provided which have the structure wherein Q is C or N, A is 0 or S, Z is O or a bond, X is CH or N and R1, R2, R2a, R2b, R2c, R3, Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

  提供化合物，其结构为Q为C或N，A为0或S，Z为O或键合，X为CH或N，R1、R2、R2a、R2b、R2c、R3、Y、x、m和n的定义如本文所述。这些化合物可用作抗糖尿病、降脂和抗肥胖剂。
• Process of preparing substituted carbamates and intermediates thereof
  申请人：Rusowicz Andrew

  公开号：US20050288343A1

  公开（公告）日：2005-12-29

  An improved process of preparing substituted carbamate derivatives, and crystalline forms thereof, useful for the treatment of dyslipidemia and diabetes, and intermediates thereof are provided.

  提供了一种改进的制备取代氨基甲酸酯衍生物及其晶体形式的方法，该方法对治疗脂质代谢异常和糖尿病有用，以及其中间体。
• J. Med. Chem. 2005, 48, 2248-2250
  作者：

  DOI：——

  日期：——
• Drugs Fut. 2004, 29, 1084-1087
  作者：

  DOI：——

  日期：——